|
|
|
|
Board of Directors |
||||
 |
Ron Taylor Chairman of the Board Ron's management and operational expertise was developed over the course of a long and successful career. Ten years at Allergan Pharmaceuticals put Ron in many different management roles throughout the organization, and in his six years at Hybritech, Inc., he was responsible for the company's operations and its international sales efforts. In 1987, Ron founded Pyxis Corporation, a venture capital financed business that he took public in 1992. Pyxis specializes in integrated software and hardware systems and services designed to improve efficiency and reduce costs associated with management and delivery of drugs and supplies in hospitals and nursing homes. Ron served as Chairman, President and Chief Executive Officer of the company until its purchase by Cardinal Health, Inc. (NYSE: CAH) in 1996 for $1 billion. After the sale and transition of Pyxis to Cardinal Health, Ron was a General Partner at Enterprise Partners Venture Capital. Ron is a director of two publicly traded companies, Watson Pharmaceuticals, Inc. (NYSE: WPI) and WestCoast Hospitality Corporation (NYSE: CVH) and is Chairman of the Board for two private companies, 3E Company and EMN8 Corporation. Ron is an avid golfer, skier, and art collector. He is a director of the Board of Trustees San Diego Museum of Contemporary Art and is Vice Chairman of the University of California, San Diego Foundation. Mr. Taylor holds a BA from the University of Saskatchewan and Masters degree from the University of California, Irvine. |
|||
 |
Linda Pinney, Asteres Inc.
Linda, Founder of Asteres Inc., was the CEO of The StartUp Lab, Inc., a venture development company serving venture capital firms and venture-backed companies. Previously she founded and was Chairman & CEO for DNA Dynamics, Inc., a top 10 finalist for San Diego’s most innovative new company of the year award in 1999. Linda was hired as the 13th employee of Pyxis Corporation and served as Vice President of Business Development for 10 years. Linda successfully developed, patented and led Pyxis into new product offerings including SupplyStation, Pyxis Data System and PyxisStation. She also created and led the Alternate Site Division to $20 million in revenue in two years. Linda took Pyxis outside healthcare constructing a licensing and equity deal with a private company pursuing industry applications of Pyxis products. Pyxis enjoyed a successful IPO in 1992 and was sold to Cardinal Health for close to $1 billion in 1996. Prior to Pyxis, Linda was in business development for Sharp HealthCare and Centinela Hospital. She has a Bachelor of Science in Genetics from U.C. Davis, and a Masters in Business & Healthcare Administration from U.S.C.
| |||
 |
Tim Wollaeger, Sanderling Ventures Tim has nearly thirty years' experience in the medical products and biotechnology fields in both corporate management and venture capital. Mr. Wollaeger joined Sanderling as a Managing Director in 2002, as head of the firm's San Diego office. Mr. Wollaeger began his career at Baxter International where his last position was Vice President and General Manager of the Company's operations in Mexico. In 1983 he joined Hybritech, Inc., San Diego's first biotechnology company, as Vice President and Chief Financial Officer. Following Hybritech's acquisition by Eli Lilly & Co in 1986, he became a founding General Partner of Biovest, a San Diego based venture capital firm. At Biovest, he helped found and remained an active Board member in Pyxis, Vical and Biosite. All three of these companies became public and Pyxis was acquired by Cardinal Health in 1996 for a $1 billion. He then helped found Columbia Hospital Corporation in 1990 and was a Senior Vice President and member of the Board of Directors until 1994, when he left to found the venture capital firm Kingsbury Capital Partners. Kingbury's investments include Aurora Biosciences, Amylin Pharmaceuticals, Phamis Software, Health Data Sciences, Senomyx, Sub-Q, TKT, Althea, and Digirad. In San Diego, he was named Entrepreneur of the Year in 1995 and Corporate Director of the Year in 2001. Mr. Wollaeger earned a B.A. in Economics from Yale in 1966, served as an officer in the U.S. Navy for three years, and earned an MBA from The Stanford Graduate School of Business in 1971.
| |||
 |
Eve M. Kurtin, PharmD, Pacific Venture Group Dr. Kurtin received a Doctorate of Pharmacy from University of Pacific and an MBA from the University of California, Los Angeles.
|
|||
 |
Stuart J.M. Collinson, Ph.D., Forward Ventures Dr. Collinson is a partner at Forward Ventures, a life science venture capital firm based in San Diego. Previously Dr. Collinson was Chairman, Chief Executive Officer and President of Aurora Biosciences Corporation where he completed a merger with Vertex Pharmaceuticals Inc., valuing Aurora at $600 million in 2001. Before Aurora, Dr. Collinson was Chief Executive Officer of privately held Andaris Limited where he completed a merger with Quadrant plc (now part of Elan Corporation plc). He held senior management positions at GlaxoWellcome plc (now GlaxoSmithKline plc) and Baxter International Inc. and was a consultant with The Boston Consulting Group. Dr. Collinson is a director of Asteres Inc., Conforma Therapeutics Inc., Essentialis Inc., GeneOhm Sciences Inc., NovaCardia Inc., Oxagen Limited, Tioga Pharmaceuticals Inc. and Vertex Pharmaceuticals Inc. Dr. Collinson was awarded an MBA from Harvard Business School and a Ph.D. in Physical Chemistry from the University of Oxford. |
|||
|
Copyright © 2008 Asteres Inc. All rights reserved. site map — info@asteres.com |
||||
